Gilead oral drug shows higher ulcerative colitis remission than Entyvio in Phase 2
Gilead Sciences reported that its oral α4β7 inhibitor achieved better remission rates than Entyvio in a Phase 2 dose-finding trial for ulcerative colitis. The company plans to begin late-stage trials of the drug next year. The data suggest the pill could compete with rival products.
Gilead Sciences has shared Phase 2 findings for an oral α4β7 inhibitor being studied in ulcerative colitis. The dose-ranging trial showed higher remission rates for the experimental pill than for Entyvio, a comparator treatment.
Gilead plans to start late-stage trials of the drug next year. The results suggest the oral option could compete with other products, though the summary provides no further details on the trial or the drug’s profile.
If confirmed in later trials, an oral ulcerative colitis drug with higher remission rates could give patients and clinicians another treatment choice. It may also increase competition among drugmakers, potentially influencing pricing and access over time. People living with ulcerative colitis, their caregivers, and health systems could feel the effects, though late-stage results will determine whether these possibilities become real.